TRK fusions
TRK fusions are seen in many solid tumours and have targeted drugs.
Genes:
- TRK1
- TRK2
- TRK3
The TRK genes are tyrosine kinase receptors.
Multiple fusion partners for each gene.
Association
- MASC.
- Secretory breast carcinoma - ETV6-NTRK3.[1]
Drugs
- Merestinib.
- Larotrectinib.
- Others.
See also
References
- ↑ Vasudev, P.; Onuma, K. (Dec 2011). "Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression.". Arch Pathol Lab Med 135 (12): 1606-10. doi:10.5858/arpa.2010-0351-RS. PMID 22129193.